AU2021207536B2 - Compositions for managing chronic obstructive pulmonary disease - Google Patents

Compositions for managing chronic obstructive pulmonary disease Download PDF

Info

Publication number
AU2021207536B2
AU2021207536B2 AU2021207536A AU2021207536A AU2021207536B2 AU 2021207536 B2 AU2021207536 B2 AU 2021207536B2 AU 2021207536 A AU2021207536 A AU 2021207536A AU 2021207536 A AU2021207536 A AU 2021207536A AU 2021207536 B2 AU2021207536 B2 AU 2021207536B2
Authority
AU
Australia
Prior art keywords
obstructive pulmonary
pulmonary disease
chronic obstructive
composition
bisdemethoxycurcumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021207536A
Other languages
English (en)
Other versions
AU2021207536A1 (en
Inventor
Sarang Bani
Muhammed Majeed
Kalyanam Nagabhushanam
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Sabinsa Group Ltd
Original Assignee
Sami Sabinsa Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Sabinsa Group Ltd filed Critical Sami Sabinsa Group Ltd
Publication of AU2021207536A1 publication Critical patent/AU2021207536A1/en
Application granted granted Critical
Publication of AU2021207536B2 publication Critical patent/AU2021207536B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021207536A 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease Active AU2021207536B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062962343P 2020-01-17 2020-01-17
US62/962,343 2020-01-17
US202063126920P 2020-12-17 2020-12-17
US63/126,920 2020-12-17
PCT/US2021/013763 WO2021146648A1 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
AU2021207536A1 AU2021207536A1 (en) 2022-08-11
AU2021207536B2 true AU2021207536B2 (en) 2025-04-10

Family

ID=76856592

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021207536A Active AU2021207536B2 (en) 2020-01-17 2021-01-16 Compositions for managing chronic obstructive pulmonary disease

Country Status (9)

Country Link
US (1) US11925606B2 (enExample)
EP (1) EP4090340B1 (enExample)
JP (1) JP7746272B2 (enExample)
KR (1) KR20220128382A (enExample)
CN (1) CN115175672B (enExample)
AU (1) AU2021207536B2 (enExample)
BR (1) BR112022014114A2 (enExample)
CA (1) CA3164013A1 (enExample)
WO (1) WO2021146648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554642A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド ビスデメトキシクルクミン組成物の抗肥満能
WO2022203721A1 (en) * 2021-03-25 2022-09-29 Muhammed Majeed Compositions and methods for inhibiting proteolytic activation of viruses
RS20220433A1 (sr) 2022-05-11 2023-11-30 Milan Prokin Višeciljni antivirusni dodatak ishrani

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204264A (ja) * 2015-04-15 2016-12-08 株式会社セラバリューズ 酸化変性ｌｄｌ複合体抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20100179103A1 (en) * 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
EP2475380A1 (en) * 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
ITMI20132169A1 (it) * 2013-12-20 2015-06-21 Thompson S R L Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata
JP2017516764A (ja) * 2014-04-18 2017-06-22 オムニアクティブ ヘルス テクノロジーズ リミテッド クルクミン組成物及びその使用
WO2016145159A1 (en) * 2015-03-10 2016-09-15 The Research Foundation For The State University Of New York Chemically modified curcumins for use in the production of lipoxins
CN105998043B (zh) * 2016-07-01 2018-11-27 吉林大学 槐属双苷在制备防治慢性阻塞性肺疾病药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204264A (ja) * 2015-04-15 2016-12-08 株式会社セラバリューズ 酸化変性ｌｄｌ複合体抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. Lelli, et al.; "Curcumin use in pulmonary diseases: State of the art and future perspectives", Pharmacological Research. 2016, 115: 133-148. DOI: 10.1016/J.PHRS.2016.11.017. *
F. Tang, et al.; "Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and ER stress through regulation of SIRT1 in a rat model", Journal of International Medical Research. 2019, 47(10): 4764-4774. *

Also Published As

Publication number Publication date
US11925606B2 (en) 2024-03-12
CN115175672A (zh) 2022-10-11
CA3164013A1 (en) 2021-07-22
NZ790708A (en) 2025-05-02
CN115175672B (zh) 2024-07-02
WO2021146648A1 (en) 2021-07-22
BR112022014114A2 (pt) 2022-09-13
JP2023512489A (ja) 2023-03-27
AU2021207536A1 (en) 2022-08-11
KR20220128382A (ko) 2022-09-20
US20210220290A1 (en) 2021-07-22
EP4090340A1 (en) 2022-11-23
EP4090340B1 (en) 2026-05-06
EP4090340A4 (en) 2024-02-21
JP7746272B2 (ja) 2025-09-30

Similar Documents

Publication Publication Date Title
EP4090340B1 (en) Compositions comprising bisdemethoxycurcumin for managing chronic obstructive pulmonary disease
Fan et al. PM2. 5 increases susceptibility to acute exacerbation of COPD via NOX4/Nrf2 redox imbalance-mediated mitophagy
Xiong et al. PM2. 5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice
ARAKAWA et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing
McMillan et al. Prolonged allergen challenge in mice leads to persistent airway remodelling
Lee et al. Camellia japonica oil suppressed asthma occurrence via GATA-3 & IL-4 pathway and its effective and major component is oleic acid
Ye et al. Aloperine suppresses LPS-induced macrophage activation through inhibiting the TLR4/NF-κB pathway
Lee et al. Grape seed proanthocyanidin extract attenuates allergic inflammation in murine models of asthma
Skevaki et al. Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features
Kang et al. Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats
Shi et al. Mitochondrial dysfunction: an emerging link in the pathophysiology of cardiorenal syndrome
JP4571952B2 (ja) 抗アレルギー組成物及び関連方法
Babu et al. Aloe vera and its two bioactive constituents in alleviation of diabetes–proteomic & mechanistic insights
Lyu et al. Anti‐inflammatory effects of reticuline on the JAK2/STAT3/SOCS3 and p38 MAPK/NF‐κB signaling pathway in a mouse model of obesity‐associated asthma
Liu et al. Nonenzymatic glycation of high‐density lipoprotein impairs its anti‐inflammatory effects in innate immunity
Yan et al. The application of proteomics and metabolomics to reveal the molecular mechanism of Nutmeg-5 in ameliorating cardiac fibrosis following myocardial infarction
Lee et al. Distribution of RANTES and interleukin-5 in allergic nasal mucosa and nasal polyps
Peng et al. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019
Liu et al. Particulate matter 2.5 triggers airway inflammation and bronchial hyperresponsiveness in mice by activating the SIRT2-p65 pathway
Saleem et al. Polystichum braunii ameliorates airway inflammation by attenuation of inflammatory and oxidative stress biomarkers, and pulmonary edema by elevation of aquaporins in ovalbumin-induced allergic asthmatic mice
Bao et al. Baicalin ameliorates radiation‐induced lung injury by inhibiting the CysLTs/CysLT1 signaling pathway
Ali et al. Modulation of immunological, biochemical, and histopathological changes of Airway Remodeling by Withania somnifera in an experimental model of allergic asthma in rats
US12594316B2 (en) Plant composition, traditional Chinese medicine composition and use thereof
Mostafa et al. The possible protective role of 6-gingerol on a model of hepatic injury induced by carbon tetrachloride in adult male albino rats: Histological and immunohistochemical study
Zhan et al. Study of the expression of GABA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)